A Double-Blind, 3-Arm, Parallel Group, Placebo- and Ropinirole-Controlled Study for SPM 962 in Advanced Parkinson's Disease Patients With Concomitant Treatment of L-dopa

Trial Profile

A Double-Blind, 3-Arm, Parallel Group, Placebo- and Ropinirole-Controlled Study for SPM 962 in Advanced Parkinson's Disease Patients With Concomitant Treatment of L-dopa

Completed
Phase of Trial: Phase III

Latest Information Update: 28 Sep 2016

At a glance

  • Drugs Rotigotine (Primary) ; Ropinirole
  • Indications Parkinson's disease
  • Focus Registrational; Therapeutic Use
  • Sponsors Otsuka Pharmaceutical
  • Most Recent Events

    • 05 Jul 2012 New source identified and integrated (ClinicalTrials.gov: US National Institutes of Health NCT01628926).
    • 04 Jul 2012 Additional trial centre, additional trial identifiers (NCT01628926, 243-08-001, JapicCTI090888), Inclusion and exclusion identified as reported by ClinicalTrials.gov.
    • 29 Jun 2012 Actual end date (1 May 2011) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top